Supernus Pharmaceuticals, Inc. will merge with Indivior Pharmaceuticals under a plan where Supernus stockholders will receive 1.5401 shares of Indivior common stock for each share held. This Merger , completed by a $1 billion Special Dividend , reshapes Shareholder stakes significantly, with Indivior stockholders owning about 56.5% of the combined company.
Key Highlights
- This exchange ratio is fixed, meaning it will not fluctuate with market conditions.
- Supernus has a market Capitalization of $2.6 billion, and its shares have seen a modest rise of 1.9% over the past month, although they remain down 1.1% year-to-date.
- The success of this merger hinges on the upcoming stockholder meetings, where Supernus and Indivior must gain necessary approvals to move forward.
Supernus Pharmaceuticals, Inc. ( Nasdaq : SUPN) has entered into a merger agreement with Indivior Pharmaceuticals, creating a combined entity that will see Supernus stockholders exchange each share for 1.5401 shares of Indivior stock. This strategic merger marks a significant shift, allowing Supernus to continue operating under its name while offering shareholders a considerable stake in the newly formed company. The deal positions Indivior stockholders with approximately 56.5% ownership post-merger, reflecting a major consolidation in the healthcare sector.
Merger Mechanics
This exchange ratio is fixed, meaning it will not fluctuate with market conditions. The transaction is subject to various conditions, including stockholder approval from both companies. Once finalized, Indivior plans to declare a special Cash Dividend totaling $1 billion for its shareholders, significantly enhancing the appeal of the merger.
Each stockholder will benefit by receiving new shares equivalent to their current holdings, ensuring a smooth transition for investors.
Current Market Context
Supernus has a market capitalization of $2.6 billion, and its shares have seen a modest rise of 1.9% over the past month, although they remain down 1.1% year-to-date. External pressures are apparent, as peers like GPCR and MBX are trading lower, down 0.3% and 2.7%, respectively, emphasizing the uniqueness of this merger's positioning.
Future Steps
The success of this merger hinges on the upcoming stockholder meetings, where Supernus and Indivior must gain necessary approvals to move forward. Both companies have urged their respective shareholders to endorse this merger agreement, expected to be a transformative event for their market presence. If approved, this merger will not only redefine their corporate structures but also set the stage for potential future growth opportunities in a consolidating healthcare market.
Investors should keep an eye on these key votes following the scheduled meetings.
Peers Moving on This News
- Structure Therapeutics Inc (GPCR) down 0.3%
- MBX Biosciences Inc (MBX) down 2.7%
- AtaiBeckley Inc (ATAI) down 0.3%
Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.






Please wait processing your request...